BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30284080)

  • 1. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
    Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
    Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
    Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002).
    Takahari D; Ito S; Mizusawa J; Katayama H; Terashima M; Sasako M; Morita S; Nomura T; Yamada M; Fujiwara Y; Kimura Y; Ikeda A; Kadokawa Y; Sano T;
    Gastric Cancer; 2020 Mar; 23(2):293-299. PubMed ID: 31515693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial.
    Hosoda K; Katada C; Ishido K; Niihara M; Ushiku H; Sakuraya M; Washio M; Wada T; Watanabe A; Harada H; Sato T; Tajima H; Kaizu T; Kosaka Y; Kato H; Sengoku N; Tanaka K; Naito T; Kumamoto Y; Sangai T; Tanabe S; Koizumi W; Yamashita K; Hiki N
    Langenbecks Arch Surg; 2020 Sep; 405(6):777-785. PubMed ID: 32617667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer.
    Fushida S; Nashimoto A; Fukushima N; Kawachi Y; Fujimura T; Kuwabara S; Musha N;
    Jpn J Clin Oncol; 2012 Feb; 42(2):131-3. PubMed ID: 22167664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).
    Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y;
    Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
    J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
    BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.
    Aoyama T; Nishikawa K; Fujitani K; Tanabe K; Ito S; Matsui T; Miki A; Nemoto H; Sakamaki K; Fukunaga T; Kimura Y; Hirabayashi N; Yoshikawa T
    Ann Oncol; 2017 Aug; 28(8):1876-1881. PubMed ID: 28486692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer.
    Tanaka Y; Kunisaki C; Izumisawa Y; Makino H; Kimura J; Sato S; Miyamoto H; Kosaka T; Ono HA; Takahashi M; Sato K; Akiyama H; Endo I
    Anticancer Res; 2018 Oct; 38(10):6015-6021. PubMed ID: 30275234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
    Iwasaki Y; Sasako M; Yamamoto S; Nakamura K; Sano T; Katai H; Tsujinaka T; Nashimoto A; Fukushima N; Tsuburaya A;
    J Surg Oncol; 2013 Jun; 107(7):741-5. PubMed ID: 23400787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
    BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS)].
    Egawa T; Kenmochi T; Ohashi M; Irino T; Mihara K; Okamura A; Inaba Y; Ito Y; Hayashi S; Nagashima A
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2470-2. PubMed ID: 21224609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
    Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
    Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
    Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
    Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
    Yoshikawa T; Aoyama T; Tanabe K; Nishikawa K; Ito Y; Hayashi T; Cho H; Miyashita Y; Tsuburaya A; Sakamoto J
    Dig Surg; 2016; 33(5):424-30. PubMed ID: 27164988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.